Cemsidomide Phase 1 Data Shows 53% ORR in Heavily Pre-treated Multiple Myeloma Patients
Summary
C4 Therapeutics announced strong Phase 1 clinical data for its cemsidomide drug in relapsed/refractory multiple myeloma, showing a 53% overall response rate and good tolerability in heavily pre-treated patients.
Key Events
-
Positive Phase 1 Cemsidomide Data
Updated results from the Phase 1 trial of cemsidomide in relapsed/refractory multiple myeloma (RRMM) were presented at the European Hematology Association (EHA) 2026 Congress.
-
High Overall Response Rate (ORR)
Cemsidomide achieved a 53% ORR at the 100 µg Recommended Phase 2 Dose (RP2D) in heavily pre-treated patients (median 7 prior lines of therapy, 75% prior CAR-T or T-cell engager therapy).
-
Deepening Responses and MRD Negativity
Responses deepened over time across the 75 µg and 100 µg dose levels, with some patients achieving stringent complete responses (sCR) and minimal residual disease (MRD) negativity.
-
Favorable Safety Profile
The drug demonstrated a well-tolerated profile with manageable neutropenia (58% Grade 3/4) and minimal discontinuations or dose reductions related to safety.
Analysis
C4 Therapeutics reported updated Phase 1 data for cemsidomide, an IKZF1/3 degrader, in relapsed/refractory multiple myeloma. The data, presented at EHA 2026, showed a 53% overall response rate (ORR) at the recommended Phase 2 dose (100 µg) in a heavily pre-treated patient population. Responses deepened over time, with some patients achieving stringent complete responses and minimal residual disease (MRD) negativity. The drug was well-tolerated, supporting its potential as a foundational therapy and for combination studies. This positive clinical update validates the company's lead asset and its development strategy.
At the time of this filing, CCCC was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $419.6M. The 52-week trading range was $1.36 to $4.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.